News
IMMX
2.240
+11.44%
0.230
Weekly Report: what happened at IMMX last week (1125-1129)?
Weekly Report · 1d ago
Immix Biopharma Reports 75% Response Rate in Relapsed/Refractory AL Amyloidosis Patients for NXC-201 Ahead of ASH Presentation
Barchart · 11/25 18:56
Immix Biopharma Presents NXC-201 Clinical Data In 16 Relapsed/Refractory AL Amyloidosis Patients At 66th American Society of Hematology (ASH) Annual Meeting; 75% (12/16) Complete Response Rate Observed In Relapsed/Refractory AL Amyloidosis Patients With Median 4 Prior Lines Of Therapy
Benzinga · 11/25 14:34
Weekly Report: what happened at IMMX last week (1118-1122)?
Weekly Report · 11/25 12:07
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
Barchart · 11/25 08:32
Weekly Report: what happened at IMMX last week (1111-1115)?
Weekly Report · 11/18 12:04
Based on the provided financial report articles, I generated the title for the article: **Consolidated Balance Sheets of [Company Name] as of December 31, 2023, March 31, 2024, and June 30, 2024, and December 31, 2022** Please note that the title may not be exact, as the provided text does not contain the company name.
Press release · 11/13 02:18
Weekly Report: what happened at IMMX last week (1104-1108)?
Weekly Report · 11/11 12:23
Immix Biopharma Inc <IMMX.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Reuters · 11/07 21:14
Weekly Report: what happened at IMMX last week (1028-1101)?
Weekly Report · 11/04 12:18
Weekly Report: what happened at IMMX last week (1021-1025)?
Weekly Report · 10/28 12:07
Weekly Report: what happened at IMMX last week (1014-1018)?
Weekly Report · 10/21 12:01
Weekly Report: what happened at IMMX last week (1007-1011)?
Weekly Report · 10/14 12:41
Weekly Report: what happened at IMMX last week (0930-1004)?
Weekly Report · 10/07 12:27
Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 10/03 11:07
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Benzinga · 10/03 10:57
Immix Biopharma’s Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook
TipRanks · 10/03 10:16
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
TipRanks · 10/02 13:35
Immix Biopharma Reports CAR-T NXC-201 To Expansion Cohort Dose Level In U.S. AL Amyloidosis Trial NEXICART-2
Benzinga · 10/02 13:33
IMMIX BIOPHARMA ADVANCES CAR-T NXC-201 TO EXPANSION COHORT DOSE LEVEL IN U.S. AL AMYLOIDOSIS TRIAL NEXICART-2
Reuters · 10/02 13:32
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).